25-28 June 2014

Barcelona, Spain

Scientific Agenda

Wednesday, 25 June, 2014

12:30

Expert discussion (by invitation only)
Scientific committee and selected experts

Session I: Presentation of selected abstracts I

Chairs: Mario Dicato, MD, Eric Van Cutsem, MD, PhD and Josep Tabernero, MD, PhD

15:00

Welcome and introduction: Congress Chairs
Mario Dicato, MD, Eric Van Cutsem, MD, PhD and Josep Tabernero, MD, PhD

15:05

Presentation of selected abstracts

Session II: Cancer of the pancreas and bile ducts

16:00

Familial pancreatic cancer

16:20

Intraductal papillary mucinous neoplasm

16:40

Surgical resection for pancreatic cancer: Anything new on the horizon?

17:00

Strategies to improve the outcome in locally advanced pancreatic cancer

17:20

Clinical case discussion

17:40

What is the optimal treatment for patients with metastatic pancreatic cancer?

18:00

Presentation of selected abstracts

18:20

New agents on the horizon in pancreatic cancer

18:40

Personalized medicine: The future in pancreatic cancer

19:00

Welcome reception

Thursday, 26 June 2014

Session III: Meet the expert concurrent presentations

8:00

Anal cancer
Cholangiocarcinoma and gall bladder cancer
Thrombosis in GI cancer (including novel anticoagulants)
GIST
Challenges and limitations in rectal cancer management
GI lymphoma

9:00

Session adjourns

Session IV: Esophageal cancer

9:10

Treatment of Barrett’s esophagus: Update on new endoscopic modalities

9:30

Which neoadjuvant treatment in GEJ?
Pro chemotherapy
Pro chemoradiotherapy

10:00

Surgery for esophageal cancer: How can we improve?

10:15

Discussion and cases

10:30

Break and poster viewing
Abstracts to be presented: Clinical/basic non-CRC abstracts

Session V: Rare tumors: Neuroendocrine tumors and gastrointestinal stromal tumors

11:00

Relevance of molecular markers for management of GIST tumors

11:20

Recommendations for the management of pancreatic NET

11:40

Recommendations for the management of small bowel NET

12:00

Liver directed therapy for liver metastases of NET

12:05

Efficacy and toxicity of peptide receptor targeted radiopeptide therapy

12:15

Presentation of selected abstracts

12:35

Efficacy and toxicity of peptide receptor targeted radiopeptide therapy

12:55

Session adjourns

13:10

Concurrent luncheon symposia begin

14:40

Concurrent luncheon symposia adjourn

Session VI: Cancer of the liver and bile ducts

14:55

Pathologic and molecular changes in HCC

15:15

How to decide on the optimal treatment algorithm for HCC?

15:35

New molecular targeted agents in HCC

15:55

Keynote lecture 1: Viruses and GI cancer

16:20

Travel Grant award ceremony

16:30

Break and poster viewing
Abstracts to be presented: Clinical/basic non-CRC abstracts

Session VII: Gastric cancer

17:00

Hereditary diffuse gastric cancer and genetic syndromes of stomach cancer: What clinicians need to know

17:20

Challenges in the surgical management of gastric cancer

17:40

Should all patients be treated with adjuvant and/or neoadjuvant treatment?

18:00

Presentation of selected abstract

18:10

What is the reference cytotoxic regimen in advanced gastric cancer?

18:25

Presentation of selected abstract

18:35

Case presentation and discussion

18:45

New targeted agents in gastric cancer

19:05

Session adjourns

Friday, 27 June 2014

Session VIII: Meet the expert concurrent presentations

Parallel with Session IX – Presentation of selected abstracts IIA, Session X – Presentation of selected abstracts IIB and Session XI: ESMO session: Focus on young medical oncologist

8:00

Peritoneal metastases: Challenges for the surgeon
Carcinoma of unknown origin
Treatment of elderly patients with GI cancer
Workshop: What are resectable liver metastases?
Mesothelioma

9:00

Session adjourns

Session IX – Presentation of selected abstracts IIA

Parallel with Session VIII: Meet the expert concurrent presentations, Session X- Presentation of selected abstracts IIB and Session XI: ESMO session: Focus on young medical oncologist

8:00

Presentation of selected abstracts

8:30

Abstract Discussion

8:40

Presentation of selected abstracts

9:20

Abstract discussion

9:30

Session adjourns

Session X – Presentation of selected abstracts IIB

Parallel with Session VIII: Meet the expert concurrent presentations, Session IX- Presentation of selected abstracts IIA and Session XI: ESMO session: Focus on young medical oncologist

8:00

Presentation of selected abstracts

8:30

Abstract Discussion

8:40

Presentation of selected abstracts

9:00

Abstract discussion

9:15

Session adjourns

Session XI: ESMO session: Focus on young medical oncologist

Parallel with Session VIII: Meet the expert concurrent presentations, Session IX – Presentation of selected abstracts IIA and Session X – Presentation of selected abstracts IIB

8:00

Session begins

8:55

ESMO Young Oncologist Committee Presentation

Session XII: Clinical trials for GI oncologists Trials and endpoints in GI cancer

Parallel with Session XIII: Special EONS nurses’ symposium: Management of patients with rectal cancer

9:00

How to balance regulations and clinical practice

9:15

Magnitude of benefit (delta and HRs)

9:45

PET

10:00

Functional imaging with MRI

10:15

Discussion

10:30

Break and poster viewing
Abstracts to be presented: Clinical/basic CRC abstracts

Session XIII: Special EONS nurses’ symposium: Management of patients with rectal cancer

Parallel with Session XII: Clinical trials for GI oncologists – Trials and endpoints in GI

9:00

Session begins

10:00

The role of patients groups and advocacy groups in colon cancer

10:20

Discussion

10:30

Break and poster viewing
Abstracts to be presented: Clinical/basic CRC abstracts

Session XIV: Multimodality therapy for rectal cancer

11:00

Imaging in rectal cancer: What is mandatory for optimal staging?

11:20

Can the pathologist judge the quality of rectal cancer surgery and treatment?

11:35

Organ-sparing surgery in rectal cancer

12:05

Which neoadjuvant chemoradiotherapy regimen in rectal cancer?

12:20

Presentation of selected abstract

12:30

How to intensify preoperative therapy in rectal cancer?
Pro RT
Pro chemo

12:45

Rectal cancer: Future directions in radiotherapy of rectal cancer

13:00

Session adjourns

13:15

Concurrent luncheon symposia begin

14:45

Concurrent luncheon symposia adjourn

Session XV: Liver and peritoneal liver metastases

15:00

Keynote lecture 2: Statistics in GI cancer: Essential principles for clinicians

15:30

Keynote lecture 3: Health economics: Essential principles for clinicians be able to afford all treatment options?

16:00

Keynote lecture 4: The WNT pathway

16:30

Break and poster viewing
Abstracts to be presented: Clinical/basic CRC abstracts

Session XVI: Liver and peritoneal metastases

17:00

Presentation of selected abstracts

17:20

Surgery for liver metastases: How far should and can the surgeon go?

17:40

Is there a role for palliative resection for the primary tumor in case of metastases?

18:00

Multidisciplinary management of peritoneal carcinomatosis from colorectal cancer: New perspectives

18:20

Liver directed therapy When and how? (Stereotactic radiotherapy, selective intrahepatic radiospheres, drug eluting beads or intrahepatic chemotherapy)

Session XVII: Poster discussion

18:40

Poster discussion session 1

18:50

Poster discussion session II

19:10

Poster discussion session IV

19:20

Session adjourns

Saturday, 28 June 2014

Session XVIII: Prevention and screening of colon cancer

8:30

Hereditary colon cancer syndromes

8:50

Screening for CRC in 2014

9:10

Chemoprevention of colon cancer

9:30

Does it matter what we eat and whether we exercise?

9:50

Break

Session XIX: Metastatic colorectal cancer

10:20

What is the best cytotoxic backbone for biologicals?

10:30

Maintenance treatment or stop and go: What is the standard?

10:35

Presentation of selected abstractsn

11:15

Abstract discussion

11:25

Presentation of selected abstracts

11:55

Abstract discussion

12:05

Which biological targeted agent and for whom?

12:25

Molecular markers beyond RAS anti-EGFR targeted agents What is new?

12:40

What to do in BRAF mutant CRC patients?

12:55

Session adjourns

13:10

Concurrent luncheon symposia begin

14:40

Concurrent luncheon symposia adjourn

Session XX: Hot topics in colon cancer

14:55

New drugs and targets in colorectal cancer

15:15

Are we making progress in the molecular taxonomy of colon cancer?

15:35

Are gene signatures ready for use in the selection of patients for adjuvant treatment?

15:55

How to improve on the adjuvant treatment in stage III colon cancer?

Session XXI: Report on expert discussion

16:15

Presentation of outcome of expert discussion: Metastatic colorectal cancer
Eric Van Cutsem, MD, PhD, Mario Dicato, MD and Josep Tabernero, MD, PhD

16:40

Adjourn